Adriamycin (doxorubicin)

Effective Date: 10/22/13
Date Developed: 9/3/13 by Albert Reeves MD
Last Approval Date 1/26/16, 1/24/17, 1/23/18, 1/22/19, 2/18/20

Adriamycin inhibits nucleotide replication and the action of DNA and RNA polymerases via nucleotide base intercalation (a form of substitution).

Prior Authorization Criteria:

Treatment of acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML) Hodgkin’s Disease, malignant lymphoma, soft tissue and bone sarcomas, thyroid cancer, small cell lung cancer, breast cancer, gastric cancer, ovarian cancer, bladder cancer, neuroblastoma, and Wilm’s tumor, as a component of multi-agent adjuvant chemotherapy for axillary node involvement following resection of primary breast cancer.

Unlabeled:

Treatment of multiple myeloma, endometrial carcinoma, uterine sarcoma, head and neck cancer, liver cancer, kidney cancer, Waldenstrom macroglobulinemia.

Note: See VCHCP Policy for Prescription Medication for Off-Label Use for details.

Dosage: Usual or typical adult dosages: I.V.: 60-75 mg/m²/dose every 21 days

Usual/typical pediatric dosages: I.V.: 35-75 mg/m²/dose every 21 days

Note: Refer to product literature for specific dosing protocols for each disease and for hepatic impairment

Note: Utilize patient’s actual body weight (full weight) for calculation of body surface area- or weight-based dosing

Dosing: Adjustment for Toxicity
The following delays and/or dose reductions have been used:
Neutropenic fever/infection: Consider reducing to 75% of dose in subsequent cycles ANC <1000/mm³: Delay treatment until ANC recovers to ≥1000/mm³
Platelets <100,000/mm³: Delay treatment until platelets recover to ≥100,000/mm³

How Supplied: 2mg/mL (5, 10, 25, 100 mL)
Precautions: acute and chronic cardiotoxicity (dysrhythmias, CHF); neutropenia; thrombocytopenia; alopecia; secondary malignancy (AML, MDS); miscellaneous (from case reports; see product literature)

References:


**Revision History:**
- Date Approved by P&T Committee: 10/22/13
- Date Reviewed/No Updates: 1/28/14 by C. Sanders MD
- Date Approved by P&T Committee: 1/28/14
- Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
- Date Approved by P&T Committee: 1/27/15
- Date Reviewed/Updated: 6/29/15 by C. Sanders, MD; R. Sterling, MD
- Date Approved by P&T Committee: 1/26/16
- Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
- Date Approved by P&T Committee: 1/24/17
- Date Reviewed/No Updates: 1/23/18 by C. Sanders, MD; R. Sterling, MD
- Date Approved by P&T Committee: 1/23/18
- Date Reviewed/No Updates: 1/22/19 by C. Sanders, MD; R. Sterling, MD
- Date Approved by P&T Committee: 1/22/19
- Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
- Date Approved by P&T Committee: 2/18/20

<table>
<thead>
<tr>
<th>Revision Date</th>
<th>Content Revised (Yes/No)</th>
<th>Contributors</th>
<th>Review/Revision Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/24/17</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/23/18</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>1/22/19</td>
<td>No</td>
<td>Catherine Sanders, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
<tr>
<td>2/18/20</td>
<td>No</td>
<td>Howard Taekman, MD; Robert Sterling, MD</td>
<td>Annual review</td>
</tr>
</tbody>
</table>